PRESS RELEASES

Year
November 06 | 2025
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 04 | 2025
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
October 27 | 2025
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
October 21 | 2025
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
October 21 | 2025
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
October 20 | 2025
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
October 19 | 2025
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
September 29 | 2025
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
August 27 | 2025
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
August 07 | 2025
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
June 23 | 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
June 13 | 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 04 | 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
May 08 | 2025
RAPT Therapeutics Reports First Quarter 2025 Financial Results
April 15 | 2025
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
March 07 | 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
March 06 | 2025
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
January 09 | 2025
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06 | 2025
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors